A new business model is needed to drive antibiotic development

June 14, 2016, Public Library of Science

The current business model for antibiotics is plagued by market failures and perverse incentives that both work against conservation efforts and provide insufficient rewards to drive the development of much-needed new treatments for resistant infection according to Kevin Outterson, from Boston University School of Law, Boston, US and Chatham House, UK, and colleagues in an Essay published in PLOS Medicine.

In their Essay the authors outline how a business model that delinks rewards from sales volume of an antibiotic could work. In addition they describe critical issues that need to be overcome to make this business model a reality so that could be developed and conserved to avoid the development of resistant bacteria.

The authors conclude, "[t]he UK's [Antimicrobial Resistance] Review, led by Lord Jim O'Neill, proposed that "a successful intervention must partially or fully 'de-link' profit from sales" ... With this growing focus on antibiotic delinkage, we see the need for a global conversation that applies delinkage principles to address access, conservation, and innovation of antibiotics in concert and not in isolation."

Explore further: A range of interventions could curb rising antibiotic resistance in India

More information: Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen J-A (2016) Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med 13(6): e1002043. DOI: 10.1371/journal.pmed.1002043

Related Stories

A range of interventions could curb rising antibiotic resistance in India

March 2, 2016
Antibiotic resistance is a global public health threat and one of particular concern in India. A mix of poor public health systems, high rates of infectious disease, inexpensive antibiotics, and rising incomes are is coming ...

Special collection presents the state of science for evaluating antibiotic resistance in agroecosystems

March 3, 2016
The World Health Organization has identified antibiotic resistance as a serious threat to human health across the world. The Journal of Environmental Quality (JEQ) recently published a special section titled "Antibiotics ...

Answer to antibiotic-resistant infections could already be on the market

April 26, 2016
The rise of antibiotic resistant bacterial pathogens is an increasingly global threat to public health. In the United States alone antibiotic resistant bacterial pathogens kill thousands every year.

Deep changes urged to avoid mass deaths from superbugs

May 19, 2016
Ten million people could die by 2050 unless sweeping global changes are agreed to tackle increasing resistance to antibiotics, which can turn common ailments into killers, a report warned Thursday.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.